LIN SUE-JEAN sold $121K of ARQT

LIN SUE-JEAN sold 4,946 shares of Arcutis Biotherapeutics, Inc. (ARQT) at $24.38 ($0.12M total) on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · LIN SUE-JEAN
Published Jun 18, 2026, 12:47 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 18, 2026, 1:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARQT
Neutral
high confidence
Mentioned
$ARQT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARQTNeutralLow
01

Why it matters

The disclosure documents a director open-market sale executed under a pre-arranged 10b5-1 plan; it is not evidence of a new discretionary view.

02

Market read

Traders may treat this as routine insider activity; without additional catalysts, it’s unlikely to drive a sustained repricing.

03

What to watch

The article doesn’t state whether other insiders bought/sold around the same window, nor does it provide context on total director holdings changes beyond the post-transaction balance.

Relevance 3/10Novelty 5/10Timing: Filed 2026-06-17 for a sale dated 2026-06-15

Background

SEC Form 4 reports an insider transaction by a director of Arcutis Biotherapeutics.

Company-level read

Ticker impact

$ARQTNeutralHigh confidence
Context

Arcutis Biotherapeutics director Lin Sue-Jean sold 4,946 shares in an open-market transaction on 2026-06-15 under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely muted unless paired with other new fundamentals.

Evidence & confidence

The filing is a Form 4 insider sale with a pre-arranged 10b5-1 plan, and the article provides no new operational/regulatory/financial catalyst.

Market effects

Minimal—single-company insider liquidity disclosure without sector-wide read-across.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated director selling can coincide with internal caution; traders may still watch for follow-on selling or lack of insider buying.

Key entities

  • Arcutis Biotherapeutics, Inc.

    Issuer of the Form 4 insider sale; ticker ARQT.

  • Lin Sue-Jean

    Director who sold 4,946 shares on 2026-06-15 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARQTHighAI 8/10

Arcutis reports trial data on infant eczema treatment candidate

Arcutis Biotherapeutics (ARQT) presented INTEGUMENT-INFANT trial data for ZORYVE cream 0.05% in treating infant atopic dermatitis. The study showed no serious adverse events, with 66.7% of infants reporting itch improvement within 4 hours. The cream is approved for children 2-5 years and is under FDA review for infants 3-24 months, with a decision expected by February 23, 2027.

$ARQTMed

Arcutis (ARQT) Q3 2026 Earnings Call Transcript

Arcutis Biotherapeutics (ARQT) reported Q3 2026 revenue of $143.9M, up 45% YoY, driven by ZORYVE franchise growth. Full-year revenue guidance raised to $535M-$545M. Net income was $8.8M, with cash and securities at $259.8M. The company plans to invest in commercial initiatives for 2027 growth, focusing on dermatology and primary care.

$ARQTMedAI 8/10

TD Cowen raises Arcutis stock price target on Zoryve momentum

TD Cowen raised its price target for Arcutis Biotherapeutics (ARQT) to $40 from $35, citing strong Zoryve sales of $144M and raised 2026 guidance. Revenue grew 11% quarter-over-quarter and 45% year-over-year, with a 91% gross profit margin. The stock trades near its 52-week high at $34.05. Arcutis reported Q3 2026 revenue of $143.9M, beating estimates, but missed profit expectations.